ATL 1101

Drug Profile

ATL 1101

Alternative Names: ATL1101

Latest Information Update: 05 Jun 2014

Price : $50

At a glance

  • Originator Murdoch Childrens Research Institute
  • Developer Antisense Therapeutics; University of British Columbia; Vancouver General Hospital
  • Class Antineoplastics; Antipsoriatics; Antisense DNA; Antisense oligonucleotides
  • Mechanism of Action Insulin-like growth factor I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Prostate cancer
  • Discontinued Psoriasis

Most Recent Events

  • 02 Jun 2014 Preclinical development is ongoing for Prostate cancer
  • 20 Jul 2012 The option period has expired for Afandin's option to license agreement with Antisense Therapeutics for ATL 1101, with no extension of the agreement available
  • 20 Jul 2012 ATL 1101 is available for licensing as of 20 Jul 2012. www.antisense.com.au
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top